Modulation of cardiac performance by motor protein gene transfer

Annals of the New York Academy of Sciences

Volumn 1123, Issue , 2008, Pages 96-104

  Herron, Todd J ^a   Devaney, Eric J ^a   Metzger, Joseph M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acute genetic engineering; Cardiac performance; Molecular motor; Myosin

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CARDIAC MYOSIN; MOLECULAR MOTOR; PROPYLTHIOURACIL;

CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; ENERGY; FAMILY THERAPY; GENE SWITCHING; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; HEART BEAT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART PERFORMANCE; HUMAN; HYDROLYSIS; HYPERTROPHIC CARDIOMYOPATHY; INFANCY; INOTROPISM; MUTANT; MUTATION; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; TRANSGENIC ANIMAL;

ANIMALIA;

EID: 41149104448     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1420.011     Document Type: Conference Paper

References (68)

1. HINKEN, A.C. & R.J. SOLARO. 2007. A dominant role of cardiac molecular motors in the intrinsic regulation of ventricular ejection and relaxation. Physiology 22: 73-80.
2. MITKA, M. 2006. Do lackluster trial findings mean new avenues are needed for heart research? JAMA 295: 611-612.
3. LOWES, B.D., W. MINOBE, W.T. ABRAHAM, et al. 1997. Changes in gene expression in the intact human heart: downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J.Clin. Invest. 100: 2315-2324.
4. MIYATA, S., W. MINOBE, M.R. BRISTOW & L.A. LEINWAND. 2000. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86: 386-390.
5. NAKAO, K., W. MINOBE, R. RODEN, et al. 1997. Myosin heavy chain gene expression in human heart failure. J. Clin. Invest. 100: 2362-2370.
6. GEISTERFER-LOWRANCE, A.A., S. KASS, G. TANIGAWA, et al. 1990. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62: 999-1006.
7. FATKIN, D. & R.M. GRAHAM. 2002. Molecular mechanisms of inherited cardiomyopathies. Physiol. Rev. 82: 945-980.
8. CARNIEL, E., M.R.G. TAYLOR, G. SINAGRA, et al. 2005. α-Myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 112: 54-59.
9. MEREDITH, C., R. HERRMANN, C. PARRY, et al. 2004. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause Laing early-onset distal myopathy (MPD1). Am. J. Hum. Genet. 75: 703-708.
10. RAYMENT, I., W.R. RYPNIEWSKI, K. SCHMIDT- BASE, et al. 1993. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 261: 50-58.
11. HOH, J.F.Y., G.P.S. YEOH, M.A.W. THOMAS, et al. 1979. Structural differences in the heavy chains of rat ventricular myosin isoenzymes. FEBS Lett. 97: 330-334.
12. POPE, B., J.F.Y. HOH & A. WEEDS. 1980. The ATPase activities of rat cardiac myosin isoenzymes. FEBS Lett. 118: 205-208.
13. SAEZ, L.J., K.M. GIANOLA, E.M. MCN ALLY, et al. 1987. Human cardiac myosin heavy chain genes and their linkage in the genome. Nucleic Acids Res. 15: 5443-5459.
14. HADDAD, F., P.W. BODELL, A.X. QIN, et al. 2003. Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching. J. Biol. Chem. 278: 37132-37138.
15. LOMPRE, A.M., B. NADAL-GINARD & V. MAHDAVI. 1984. Expression of cardiac alpha and beta-myosin heavy chain genes is developmentally and hormonally regulated. J. Biol. Chem. 259: 6437-6446.
16. HARRIS, D.E., S.S. WORK, R.K. WRIGHT, et al. 1994. Smooth, cardiac, and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J. Muscle Res. Cell Motil. 15: 11-19.
17. VAN BUREN, P., D.E. HARRIS, N.R. ALPERT. 1995. Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ. Res. 77: 439-444.
18. MALMQVIST, U.P., A. ARONSHTAM & S. LOWEY. 2004. Cardiac myosin isoforms from different species have unique enzymatic and mechanical properties. Biochemistry 43: 15058-15065.
19. PALMITER, K.A., M.J. TYSKA, D.E. DUPUIS, et al. 1999. Kinetic differences at the single molecule level account for the functional diversity of rabbit cardiac myosin isoforms. J. Physiol. (Lond.) 519: 669-678.
20. HASENFUSS, G., L.A. MULIERI, E.M. BLANCHARD, et al. 1991. Energetics of isometric force development in control and volume- overload human myocardium: comparison with animal species. Circ. Res. 68: 836-846.
21. HOLUBARSCH, C., R.P. GOULETTE, R.Z. LITTEN, et al. 1985. The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ. Res. 56: 78-86.
22. RUNDELL, V.L.M., V. MANAVES, A.F. MARTIN, et al. 2005. Impact of β-myosin heavy chain isoform expression on cross-bridge cycling kinetics. Am. J. Physiol. Heart Circ. Physiol. 288: H896-H903.
23. TANG, Y.D., J.A. KUZMAN, S. SAID, et al. 2005. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation 112: 3122-3130.
24. HERRON, T.J., F.S. KORTE & K.S. MCDONALD. 2001. Loaded shortening and power output in cardiac myocytes are dependent on myosin heavy chain isoform expression. Am. J. Physiol. Heart Circ. Physiol. 281: H1217-H1222.
25. 2+-activated tension development in single adult cardiac myocytes. Circ. Res. 84: 1310-1317.
26. KORTE, F.S., T.J. HERRON, M.J. ROVETTO, et al. 2005. Power output is linearly related to MyHC content in rat skinned myocytes and isolated working hearts. Am. J. Physiol. Heart. Circ. Physiol. 289: H801-H812.
27. RUNDELL, V.L.M., D.L. GEENEN, P.M. BUTTRICK, et al. 2004. Depressed cardiac tension cost in experimental diabetes is due to altered myosin heavy chain isoform expression. Am. J. Physiol. Heart Circ. Physiol. 287: H408-H413.
28. MERCADIER, J.J., A.M. LOMPRE, C. WISNEWSKY, et al. 1981. Myosin isoenzymic changes in several models of rat cardiac hypertrophy. Circ. Res. 49: 525-532.
29. FITZSIMONS, D.P., J.R. PATEL & R.L. MOSS. 1999. Aging-dependent depression in the kinetics of force development in rat skinned myocardium. Am. J. Physiol. Heart Circ. Physiol. 276: H1511-H1519.
30. MASAKI, H., T. IMAIZUMI, S. ANDO, et al. 1993. Production of chronic congestive heart failure by rapid ventricular pacing in the rabbit. Cardiovasc. Res. 27: 828-831.
31. WANG, J., X. GUO & N.S. DHALLA. 2004. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim. Biophys. Acta 1690: 177-184.
32. LOWES, B.D., E.M. GILBERT, W.T. ABRAHAM, et al. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346: 1357-1365.
33. RASTOGI, S., S. MISHRA, R. GUPTA, et al. 2005. Reversal of maladaptive gene program in left ventricular myocardium of dogs with heart failure following long-termtherapy with the Acorn cardiac support device. Heart Failure Rev. 10: 157-163.
34. HERRON, T.J. & K.S. MCDONALD. 2002. Small amounts of α-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ. Res. 90: 1150-1152.
35. JAMES, J., L. MARTIN, M. KRENZ, et al. 2005. Forced expression of α-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions. Circulation 111: 2339-2346.
36. KRENZ, M. & J. ROBBINS. 2004. Impact of beta-myosin heavy chain expression on cardiac function during stress. J. Am. Coll. Cardiol. 44: 2390-2397.
37. IZUMO, S., B. NADAL-GINARD & V. MAHDAVI. 1986. All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific manner. Science 231: 597-600.
38. FITZSIMONS, D.P., J.R. PATEL & R.L. MOSS. 1998. Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium. J. Physiol. (Lond.) 513: 171-183.
39. KORTE, F.S., T.J. HERRON, M.J. ROVETTO, et al. 2005. Power output is linearly related to myosin heavy chain content in rat skinned myocytes and isolated working hearts. Am. J. Physiol. Heart Circ. Physiol. 289: H801-H812.
40. 2+ ATPase mRNA in striated muscle. Mol. Cell. Endocrinol. 87: 87-93.
41. CARR, A.N, & E.G. KRANIAS. 2002. Thyroid hormone regulation of calcium cycling proteins. Thyroid 12: 453-457.
42. ARAI, M., N.R. ALPERT, D.H. MACLENNAN, et al. 1993. Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ. Res. 72: 463-469.
43. HASENFUSS, G., H. REINECKE, R. STUDER, et al. 1994. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75: 434-442.
44. 2+ uptake but decreases myocyte shortening. Circulation 110: 3553-3559.
45. TARDIFF, J.C., T.E. HEWETT, S.M. FACTOR, et al. 2000. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am. J. Physiol. Heart Circ. Physiol. 278: H412-H419.
46. MICHELE, D.E. & J.M. METZGER, 2000. Contractile dysfunction in hypertrophic cardiomyopathy: elucidating primary defects of mutant contractile proteins by gene transfer. Trends Cardiovasc. Med. 10: 177-182.
47. HERRON, T.J., R. VAN DEN BOOM, E. FOMICHEVA, et al. 2007. Calcium-independent negative inotropy by β-myosin heavy chain gene transfer in cardiac myocytes. Circ. Res. 100: 1182-1190.
48. TAJSHARGHI, H., L.E. THORNELL, C. LINDBERG, et al. 2004. Myosin storage myopathy associated with a heterozygous missense mutation in MYH7. Ann. Neurol. 54: 494-500.
49. BOHLEGA, S., S.N. BU-AMERO, S.M. WAKIL, et al. 2004. Mutation of the slow myosin heavy chain rod domain underlies hyaline body myopathy. Neurology 62: 1518-1521.
50. RICHARD, P., P. CHARRON, L. CARRIER, et al. 2003. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107: 2227-2232.
51. RAYMENT, I., H.M. HOLDEN, J.R. SELLERS, et al. 1995. Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 92: 3864-3868.
52. FANANAPAZIR, L., M.C. DALAKAS, F. CYRAN, et al. 1993. Missense mutations in the β-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 90: 3993-3997.
53. WATKINS, H., A. ROSENZWEIG, D.S. HWANNG, et al. 1992. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326: 1108-1114.
54. BLANCHARD, E., C. SEIDMAN, J.G. SEIDMAN, et al. 1999. Altered crossbridge kinetics in the α MHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circ.Res. 84: 475-483.
55. CUDA, G., L. FANANAPAZIR, W.S. ZHU, et al. 1993. Skeletal muscle expression and abnormal of beta-myosin in hypertrophic cardiomyopathy. J. Clin. Invest. 91: 2861-2865.
56. CUDA, G., L. FANANAPAZIR, N.D. EPSTEIN, et al. 1997. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta myosin heavy chain genemutation in hypertrophic cardiomyopathy. J. Muscle Res. Cell Motil. 18: 275-283.
57. SWEENEY, H.L., A.J. STRACESKI, L.A. LEINWAND, et al. 1994. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J. Biol. Chem. 269: 1603-1605.
58. PALMER, B.M., D.E. FISHBAUGHER, J.P. SCHMITT, et al. 2004. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 287: H91-H99.
59. TYSKA, M.J., E. HAYES, M. GIEWAT, et al. 2000. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ. Res. 86: 737-744.
60. YAMASHITA, H., M.J. TYSKA, D.M. WARSHAW, et al. 2000. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J. Biol. Chem. 275: 28045-28052.
61. DEBOLD, E.P., J.P. SCHMITT, J.R. MOORE, et al. 2007. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse α-cardiac myosin in the laser trap assay. Am. J. Physiol. Heart Circ. Physiol. 00128.
62. 2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106: 1351-1359.
63. GAO, W.D., N.G. PEREZ, C.E. SEIDMAN, et al. 1999. Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. J. Clin. Invest. 103: 661-666.
64. SEMSARIAN, C., I. AHMAD, M. GIEWAT, et al. 2002. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in amouse model. J. Clin. Invest. 109: 1013-1020.
65. MARIAN, A.J., Y. WU, D.S. LIM, et al. 1999. A transgenic rabbit model for human hypertrophic cardiomyopathy. J. Clin. Invest. 104: 1683-1692.
66. MARIAN, A.J., Q.T. YU, D.L. MANN, et al. 1995. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiacmyocytes. Circ. Res. 77: 98-106.
67. WANG, Q., C.L. MONCMAN & D.A. WINKELMANN. 2003. Mutations in the motor domain modulate myosin activity and myofibril organization. J. Cell Sci. 116: 4227-4238.
68. AGBULUT, O., A. HUET, N. NIEDERLANDER, et al. 2007. Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin. J. Biol. Chem. 282: 10465-10471.